Key result
Statin use linked to substantially lower short- and long-term mortality in sepsis-associated encephalopathy.
Why the study?
Does statin therapy reduce mortality in ICU patients with sepsis-associated encephalopathy?
Cohort (n=4,707)
Does statin therapy reduce mortality in ICU patients with sepsis-associated encephalopathy?
Statin therapy is associated with reduced short- and long-term mortality in ICU patients with sepsis-associated encephalopathy.
Background Sepsis-associated encephalopathy (SAE) is a severe neurological complication of sepsis. Statins may exerted protective effects in sepsis and its complications by reducing the dysregulated inflammatory response. However, it remains unknown whether statins provide any protective effect on SAE. Methods The data for this study were extracted from the MIMIC-IV database. Cox proportional hazards regression models were constructed to assess the association between statin therapy and mortality rate for in-hospital, 30-day, 90-day, 180-day, and 365-day. Kaplan–Meier survival curves were used to estimate survival probabilities between the non-statin group and statin group. Subgroup analysis was conducted to investigate potential variations in the effects of statin treatment on clinical outcomes among different groups. Results A total of 4,707 patients with SAE were included in the study, with 2,387 in the non-statin group and 2,320 in the statin group. The findings indicated that the use of statins was linked to a considerable decrease in mortality rates. Patients who were administered statins experienced lower in-hospital mortality and demonstrated enhanced survival rates at 30, 90, 180, and 365 days when compared to those not receiving statins. Further analysis of atorvastatin showed that the subgroup exhibited a similarly consistent reduction in mortality across all time points in comparison to the non-statin group. Interestingly, the protective effect associated with statin use remained significant regardless of the statin type, dosage, or exposure time. Conclusion The use of statins was associated with short-term and long-term mortality among SAE patients admitted to the ICU. This association was observed irrespective of statin type, dosage, or exposure time. It is necessary to conduct large-scale prospective studies to further explore the relationship between statins and the prognosis of patients with SAE.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) conducted a cohort in Sepsis-associated encephalopathy (n=4,707). Statins vs. No statins was evaluated on In-hospital, 30-day, 90-day, 180-day, and 365-day mortality. Statin use was associated with a considerable decrease in in-hospital, 30-day, 90-day, 180-day, and 365-day mortality among ICU patients with sepsis-associated encephalopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: